On September 5, 2019 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, reported it will present a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference to be held September 8-10 in New York, NY (Press release, Aeglea BioTherapeutics, SEP 5, 2019, View Source [SID1234539313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Date: Monday, September 9, 2019
Time: 5:30 p.m. ET
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: Lotte New York Palace Hotel, New York
Webcast: http://ir.aegleabio.com/events/event-details/hc-wainwright-co-21st-annual-global-investment-conference

To access the live and archived audio webcast, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.

On September 5, 2019 Agilent Technologies, Inc. (NYSE: A) reported the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $500 million (Press release, Agilent, SEP 5, 2019, https://www.agilent.com/about/newsroom/presrel/2019/05sep-gp19020.html [SID1234539330]). The offering is being conducted under an automatic shelf registration statement on file with the Securities and Exchange Commission. The notes will mature in September 2029 and will bear interest at an annual rate of 2.750 percent. The offering is expected to close on September 16, 2019, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The estimated net proceeds of the offering are expected to be approximately $492.8 million. Agilent intends to use the net proceeds from the offering and cash on hand to fund the redemption of its outstanding 5.00% senior notes due 2020.

Barclays Capital Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers.

Copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained from:

Barclays Capital Inc.
745 Seventh Avenue
New York, NY 10019
Telephone: (888) 603-5847

J.P. Morgan Securities LLC
383 Madison Avenue
New York, NY 10179
Telephone: (212) 834-4533

MUFG Securities Americas Inc.
1221 Avenue of the Americas, 6th Floor
New York, NY 10020-1001
Telephone: (877) 649-6848

Electronic copies of the prospectus supplement and accompanying prospectus are or will be available for free by visiting EDGAR on the Securities and Exchange Commission website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

On September 5, 2019 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, reported the Company’s CEO Dr. Pnina Fishman will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City (Press release, Can-Fite BioPharma, SEP 5, 2019, https://ir.canfite.com/news/detail/864/can-fite-to-present-at-h-c-wainwright-21st-annual-global-investment-conference-on-september-10-2019 [SID1234539298]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Fishman will present on Tuesday, September 10th at 3:00 p.m. in the Kennedy I room, 4th floor. Company executives will also conduct one-on-one meetings with institutional investors.

On September 5, 2019 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), reported that it will present at the Rodman & Renshaw 21st Annual Global Investment Conference (Press release, Actinium Pharmaceuticals, SEP 5, 2019, View Source [SID1234539314]). The conference is being held at the Lotte New York Palace Hotel in New York City on September 8-10, 2019. Details of Actinium’s presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, September 10, 2019
Time: 4:40 PM ET
Room: Holmes I (4th Floor)
Venue: Lotte New York Palace Hotel

Members of Actinium’s Executive team will be available for 1-on-1 meetings with conference attendees. Those interested in scheduling a meeting with Actinium may do so by contacting Steve O’Loughlin, Actinium’s Principal Financial Officer via email at [email protected].

On September 5, 2019 Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), reported that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment conferences in September 2019 (Press release, Sorrento Therapeutics, SEP 5, 2019, http://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-participate-multiple-investment-conferences [SID1234539331]). Dr. Ji will provide corporate updates to investors, focusing on the core clinical pipeline progress for Sorrento Therapeutics immuno-oncology and pain programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the upcoming events:

Bio Century Newsmakers in the Biotech Industry
Date: Friday, September 6th
Time: 10:40 AM Eastern Time
Location: Millennium Broadway Hotel
Times SquareRoom 404/405, NY
Webcast: View Source

21st Annual Global Investment Conference Sponsored by H.C. Wainwright
Date: Tuesday, September 10th
Time: 10:50 AM Eastern Time
Location: Lotte New York Palace, Holmes II (4th Floor), NY
Webcast:View Source

Rambam Foundation Healthcare Conference
Topic: Off the shelf cellular therapies
Date: Tuesday, September 10th
Time: 12:30 PM Eastern Time
Location: The Mansion: 107 E 16th NY